Can Phosphate Binders Drive DaVita Stock Before Q2 Earnings?

DaVita (DVA) is poised for its Q2 2025 earnings, with Zacks consensus estimates projecting revenues of $3.30 billion (+3.5% YoY) and EPS of $2.70 (+4.3% YoY), following a 14.3% EPS beat in Q1. Performance is significantly boosted by the favorable impact of phosphate binders, driven by CMS transition, expected to contribute to full-year operating income at the upper end of guidance. However, supply constraints in peritoneal dialysis solutions are anticipated to negatively impact new patient starts and 2025 volume growth. Despite this headwind, DVA's valuation at 0.8x forward P/S, a notable discount to the industry average of 2.6x, coupled with a positive Earnings ESP of +6.67% and a Zacks Rank #3, indicates a high probability of an earnings beat and continued investment appeal.

Analysis

DaVita's outlook ahead of its second-quarter 2025 earnings reveals a positive operational catalyst tempered by a significant supply chain headwind. A key driver of expected performance is the CMS transition of phosphate binders into the dialysis benefit, which has led management to anticipate full-year operating income from this segment at the upper end of its $0 to $50 million guidance range. This tailwind supports consensus estimates for Q2 revenue of $3.30 billion (+3.5% YoY) and EPS of $2.70 (+4.3% YoY). However, the company faces an offsetting challenge from supply constraints in peritoneal dialysis (PD) solutions, which management has confirmed is negatively impacting new patient starts and is expected to suppress volume growth for the full year. Despite this concern, predictive models indicate a high probability of an earnings beat, supported by a positive Earnings ESP of +6.67%. From a valuation perspective, DaVita trades at a compelling discount with a forward price-to-sales ratio of 0.8x, substantially below the industry average of 2.6x. While its three-month stock gain of 1.1% has outpaced its direct healthcare sub-sector, it significantly lags the S&P 500's 13.9% growth, suggesting potential for re-rating on positive execution.

Key Decisions for Investors

• Given the model's prediction of an earnings beat, underpinned by a +6.67% Earnings ESP, investors could consider establishing or adding to positions ahead of the Q2 report to capture potential upside.
• The stock's valuation at a forward P/S of 0.8x, a significant discount to the 2.6x industry average, presents a potentially attractive entry point for value-oriented investors, contingent on the company meeting or exceeding its earnings estimates.
• Investors must closely monitor management's commentary regarding the peritoneal dialysis supply constraints, as any update on the resolution of this issue will be a key determinant of future volume growth and stock performance beyond the immediate earnings release.